Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV

Table 1 Main Characteristics of the study population

Characteristics	Total
	N = 486
Gender, n (%)
Female	139 (28.6%)
Age, years, median (range)	37 (18, 74)
Mode of HIV transmission, n (%)
Homosexual contacts	128 (26.3%)
Heterosexual contacts	232 (47.5%)
IDU	103 (21.2%)
Other/unknown	23 (4.7%)
CD4 count, cells/mmc, median (range)	256 (21180)
CD4 nadir, cell/mmc, median (IQR)	242 (121–336)
Viral load, log10 copies/mL, median (IQR)	4.8 (4.1, 5.2)
Hepatitis co-infection, n (%)
Negative	176 (36.1%)
Positive	97 (19.9%)
Not tested	215 (44.1%)
Time from HIV diagnosis to cART, months Median (IQR)	44 (38, 50)
Calendar year of starting cART, median (range)	2003 (1998, 2010)
Clinical Follow-up time^a, months Median (IQR)	79.0 (30.0, 134.0)

Note: IQR Interquartile range, IDU Injection drug users, cART Combination of antiretroviral therapy. ^aClinical follow-up time: time between cART initiation and the clinical event or for those who did not develop any of the endpoint-defining events, time between cART initiation and last CD4 count or available visit

ISSN: 1471-2334